Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000PUBT·10 hours agoHROWL0.00%HROW-1.39%
HC Wainwright Issues Pessimistic Outlook for Harrow EarningsMarket Beat·Aug 14 at 07:13 AMHROW-1.39%HROWM0.00%
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW)Market Beat·Aug 13 at 06:42 AMHROWM0.00%HROW-1.39%
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings MissMarket Beat·Aug 11 at 09:20 AMHROW-1.39%HROWM0.00%
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipelineQuartr·Aug 10 at 09:05 PMHROWL0.00%HROWM0.00%
Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term MissTip Ranks·Aug 10 at 05:45 PMHROWL0.00%HROW-1.39%
Harrow Q2 FY26 net loss widens to $17.27 million; revenue rises 11% to $70.66 millionPUBT·Aug 10 at 03:07 PMHROW-1.39%HROWM0.00%
B. Riley Securities Keeps Their Buy Rating on Harrow Health (HROW)Tip Ranks·Aug 10 at 08:48 AMHROW-1.39%HROWM0.00%
Arista Networks Stock Leads Fast Growth Picks With High Insider OwnershipSimplywall·Aug 6 at 04:31 PMHROWM0.00%ANET+1.50%
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlookbenzinga_article·Aug 6 at 12:56 PMVTRS0.00%HROWL0.00%
Harrow to buy dry eye nasal spray Tyrvaya from Viatris for up to $100 millionPUBT·Aug 6 at 06:12 AMHROW-1.39%HROWL0.00%
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026Unusual Whales·Jul 27 at 06:02 AMHROW-1.39%HROWM0.00%
Harrow updates financial calendar with upcoming quarterly results release and investor callPUBT·Jul 27 at 06:02 AMHROWL0.00%HROW-1.39%
